Indivior Pharmaceuticals, Inc. (INDV) FY2026 Q3 P&L / Income Statement
Published Source: Form 10-Q on SEC EDGAR filed (opens in a new tab)
Revenue by Business Segment by Geography
Swipe to see the full flow
Chart details
Indivior Pharmaceuticals, Inc. (INDV) FY2026 Q3 P&L / Income Statement
Income statement for 2026-07-01 through 2026-09-30. View: Segments by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.
- Net revenue
- 356,000,000 US dollars
- Cost of sales
- 51,000,000 US dollars
- Gross profit
- 305,000,000 US dollars
- Total operating expenses
- 125,000,000 US dollars
- Operating income
- 180,000,000 US dollars
- Other income (expense), net (calculated)
- 2,000,000 US dollars
- Income before income taxes
- 182,000,000 US dollars
- Income tax expense (benefit)
- 45,000,000 US dollars
- Net income
- 137,000,000 US dollars
- Reportable Segment - UNITED STATES
- 307,000,000 US dollars
- Reportable Segment - Rest of World
- 48,000,000 US dollars
- Undisclosed (calculated)
- 1,000,000 US dollars
- Selling, general and administrative
- 119,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn.
- Research and development
- 5,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn.
Chart connections
- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.

Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG
Product waitlist
Health Check and Teardown for your own company
A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!
